Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Onishi, Akira; Jinno, Sadao; Hara, Ryota; Son, Yonsu; Amuro, Hideki; Takeuchi, Tohru; Yoshikawa, Ayaka; Katayama, Masaki; Yamamoto, Keiichi; Okita, Yasutaka; Hirao, Makoto; Etani, Yuki; Kumanogoh, Atsushi; Okada, Seiji; Nakata, Ken

doi:https://doi.org/10.1038/s41598-021-04075-0

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi et al.

Scientific Reports, 2022, 12(1), 134

アクセス数:3,245件（2025-10-24 05:58 集計）

固定URL: https://hdl.handle.net/11094/93206

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
SciRep_12_1	pdf	なし	992 KB	113	2023.11.28

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000010437402 1000010437402 Scopus Author ID 55456655500 55456655500 著者名 Hirano, Toru
	NRID 1000010815658 1000010815658 Scopus Author ID 56655338200 56655338200 著者名 Maeda, Yuichi
	著者名 Yamamoto, Wataru
	NRID 1000060512845 1000060512845 著者名 Hashimoto, Motomu
	NRID 1000060806793 1000060806793 著者名 Murata, Koichi
	NRID 1000060634269 1000060634269 著者名 Onishi, Akira
	著者名 Jinno, Sadao
	NRID 1000010597107 1000010597107 著者名 Hara, Ryota
	著者名 Son, Yonsu
	著者名 Amuro, Hideki
	NRID 1000010330078 1000010330078 著者名 Takeuchi, Tohru
	NRID 1000020850069 1000020850069 著者名 Yoshikawa, Ayaka
	著者名 Katayama, Masaki
	NRID 1000070416387 1000070416387 著者名 Yamamoto, Keiichi
	著者名 Okita, Yasutaka
	NRID 1000010527708 1000010527708 Scopus Author ID 8883255100 8883255100 著者名 Hirao, Makoto
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 Scopus Author ID 57209857251 57209857251 著者名 Etani, Yuki
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 著者名 Kumanogoh, Atsushi
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 著者名 Okada, Seiji
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 著者名 Nakata, Ken
内容	Ebina K., Hirano T., Maeda Y., et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific Reports 12, 134 (2022); https://doi.org/10.1038/s41598-021-04075-0.
抄録	This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.
出版者	Nature Research
収録物名	Scientific Reports
巻(号)	12(1)
ページ	134
刊行年月	2022-01-07
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93206
eISSN	20452322
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1038/s41598-021-04075-0
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Scientific Reports. 2022, 12(1), p. 134
DC.title	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
DC.creator	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Son, Yonsu
	Amuro, Hideki
	Takeuchi, Tohru
	Yoshikawa, Ayaka
	Katayama, Masaki
	Yamamoto, Keiichi
	Okita, Yasutaka
	Hirao, Makoto
	Etani, Yuki
	Kumanogoh, Atsushi
	Okada, Seiji
	Nakata, Ken
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-01-07
DC.identifier	https://doi.org/10.1038/s41598-021-04075-0
DC.description	Ebina K., Hirano T., Maeda Y., et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific Reports 12, 134 (2022); https://doi.org/10.1038/s41598-021-04075-0.
DCTERMS.abstract	This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93206
citation_title	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
citation_author	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Son, Yonsu
	Amuro, Hideki
	Takeuchi, Tohru
	Yoshikawa, Ayaka
	Katayama, Masaki
	Yamamoto, Keiichi
	Okita, Yasutaka
	Hirao, Makoto
	Etani, Yuki
	Kumanogoh, Atsushi
	Okada, Seiji
	Nakata, Ken
citation_publisher	Nature Research
citation_language	英語
citation_date	2022-01-07
citation_journal_title	Scientific Reports
citation_volume	12
citation_issue	1
citation_firstpage	134
citation_doi	https://doi.org/10.1038/s41598-021-04075-0
citation_public_url	https://hdl.handle.net/11094/93206

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

閲覧可能ファイル

論文情報

論文詳細を表示